Clinical trials: Mouth Breathing
Allergic Bronchopulmonary Aspergillosis
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
The primary safety objectives were: Part 1: To determine the safety and tolerability of single doses of ZP-059 in healthy subjects Part 2: To determine the safety and tolerability of multiple doses of ZP-059 in subjects with mild…
- Trial name
- NCT04229303
- Testing
- Voriconazole inhaled, oral voriconazole
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
Asthma
Study of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma
Study of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects with Mild Asthma
- Trial name
- NCT03574805
- Testing
- PRS-060
- Where
- 4 sites in Australia
- Volunteers
- 76 people
- Sponsor
- Pieris Australia Pty Ltd
Snoring, Obstructive Sleep Apnea
Intraoral Tongue Stimulation for Treatment of Primary Snoring
Intraoral Neuromuscular Training for Treatment of Snoring Objective Studies show that improving pharyngeal muscle tone can ameliorate obstructive sleep apnoea (OSA) and snoring.
- Trial name
- NCT03829956
- Testing
- Intraoral tongue stimulator (Snoozeal)
- Where
- United Kingdom
- Volunteers
- 115 people
- Sponsor
- Signifier Medical Technologies
Asthma
GSK2190915 Moderate to Severe Asthma Study
A randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of treatment with GSK2190915, a FLAP inhibitor, as add-on to current inhaled corticosteroid therapy in patients with moderate to severe…
- Trial name
- NCT00850642
- Testing
- GSK2190195 100mg
- Where
- 8 sites in Canada, United Kingdom
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
Asthma
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with…
- Trial name
- FAROS (NCT07525375)
- Testing
- GP MDI, BFF MDI
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Asthma
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium…
- Trial name
- NCT01311661
- Testing
- Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily
- Where
- 36 sites in United States, Austria and 4 more
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study Estimating The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers
The purpose of this study is to investigate the time course of PF-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers.
- Trial name
- NCT00928278
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects
This is an open-label,partially randomized, four-period study in healthy male subjects to assess the bioavailability and pharmacokinetics of a single dose of AZD7594 when administered intravenously, orally and inhaled via two…
- Trial name
- NCT02648438
- Testing
- AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma, COPD
An Open Study to Assess the Robustness of the CRC749 Inhaler
To confirm the robustness of the CRC749 inhaler.
- Trial name
- NCT02474017
- Testing
- MGR001, CRC749 inhaler
- Where
- 2 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Mylan Pharma UK Ltd.
Pulmonary Disease, Chronic Obstructive
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD
- Trial name
- NCT01533922
- Testing
- Tiotropium, Olodaterol, tiotropium + olodaterol
- Where
- 44 sites in United States, Argentina and 8 more
- Volunteers
- 295 people
- Sponsor
- Boehringer Ingelheim
Obstructive Sleep Apnea
RPMO2 Oximeter Accuracy During Sleep 1 Trial
The goal of this observational study is to validate the accuracy of the RPMO2 OSA Device's oxygen desaturation index in individuals with obstructive sleep apnea versus the gold standard, in-lab polysomnography.
- Trial name
- ROADS-1 (NCT07397780)
- Testing
- RPMO2 OSA Device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- ProSomnus Sleep Technologies
Pulmonary Disease, Chronic Obstructive
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end…
- Trial name
- NCT01040728
- Testing
- Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim
Rhinitis, Allergic, Perennial
LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)
Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)
- Trial name
- NCT00160589
- Testing
- Levocetirizine
- Volunteers
- 729 people
- Sponsor
- UCB Pharma
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Pulmonary Disease, Chronic Obstructive, Lung Diseases
A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
PF-03635659 is being developed for the treatment of chronic obstructive pulmonary disease. This is a study to examine the safety, pharmacokinetics and pharmacodynamics of PF-03635659 in patients with Chronic Obstructive Pulmonary…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Respiratory Tract Diseases, Chronic Obstructive Airway Disease
- Trial name
- NCT01033487
- Testing
- active comparator, Low Dose PF-03635659, Mid Dose PF-03635659
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Pfizer
Amyotrophic Lateral Sclerosis
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale.
- Trial name
- REFALS (NCT03505021)
- Testing
- Levosimendan
- Where
- 104 sites in United States, Australia and 12 more
- Volunteers
- 496 people
- Sponsor
- Orion Corporation, Orion Pharma
LPS Challenge, Neutrophils
Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge
Study to investigate the effect of a single dose of AZD7624 on inflammation caused by an endotoxin challenge.
- Trial name
- NCT01937338
- Testing
- AZD7624
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
Study of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects
A Dose Escalating Study of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects
- Trial name
- NCT03384290
- Testing
- PRS-060
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pieris Australia Pty Ltd
Type 2 Diabetes
Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Insulin-naive subjects with Type 2 Diabetes Mellitus who are sub-optimally controlled on either maximum tolerated dose of metformin or maximum tolerated dose of metformin plus one or two other oral anti-diabetic medications will…
- Trial name
- NCT01451398
- Testing
- Technosphere® Insulin, Technosphere Powder
- Where
- 76 sites in United States, Brazil and 2 more
- Volunteers
- 353 people
- Sponsor
- Mannkind Corporation
Snoring, Sleep Apnea, Obstructive
Efficacy of Intra-oral Neuromuscular Stimulation Training on Snoring and Mild Sleep Apnoea
It has been shown that a common cause for snoring and throat obstruction (obstructive sleep apnoea (OSA)) is excessive loss of muscle tone in the throat when the investigators go to sleep.
- Trial name
- NCT04392765
- Testing
- eXciteOSA
- Where
- 6 sites in Canada, Germany and 2 more
- Volunteers
- 200 people
- Sponsor
- Signifier Medical Technologies